Merck's (MRK +0.4%) MK-8931 Alzheimer's drug has entered Phase II trials, the company announces....

|About: Merck & Co Inc. (MRK)|By:, SA News Editor

Merck's (MRK +0.4%) MK-8931 Alzheimer's drug has entered Phase II trials, the company announces. The drug attempts to prevent a worsening of Alzheimer's by blocking production of a protein believed to contribute to the disease. Eli Lilly (LLY) has reported positive Phase III trial results for its solanezumab Alzheimer's drug, when administered to patients with mild symptoms.